Sridhar Kavela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sridhar Kavela has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Syed M. Faisal
Laboratory of Vaccine Immunology, National Institute of Animal Biotechnology
5 shared publications - Sirassu Narsimha
Department of Chemistry, Chaitanya (Deemed to be University), Hyderabad, Telangana, India
4 shared publications - Jusail Cp
Laboratory of Vaccine Immunology, National Institute of Animal Biotechnology, Hyderabad, India
3 shared publications - Mohammad Kadivella
Laboratory of Vaccine Immunology, National Institute of Animal Biotechnology, Hyderabad, India
3 shared publications Ravikumar Kapavarapu
Department of Pharmaceutical Chemistry and Phytochemistry, Nirmala College of Pharmacy
3 shared publications- Vivek P. Varma
Laboratory of Vaccine Immunology, National Institute of Animal Biotechnology, Hyderabad 500032, India
3 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Springer Nature in Research Square
Therapeutic Efficacy of DSP_SK1260, an Immunomodulatory Peptide, in Experimental Models of Sepsis
Sepsis remains a significant healthcare challenge with limited effective treatments. In the present study, we investigated the therapeutic potential of DSP_SK1260, a novel compound with anti-inflammatory properties, in two sepsis models: E. coli BL21-induced septic shock and Caecal ligation and puncture (CLP) induced polymicrobial sepsis. In septic shock model, DSP_SK1260 administration before infection reduced proinflammatory cytokines, prevented disseminated intravascular coagulation (DIC), and improved survival rates in mice. Furthermore, when DSP_SK1260 was administered after sepsis induction, it effectively reduced TNF-α levels, improved coagulation parameters, and increased fibrinogen, platelet, and white blood cell counts. Therapeutic DSP_SK1260 treatment also enhanced survival in septic mice. In polymicrobial sepsis model induced by CLP, DSP_SK1260 treatment reduced TNF-α levels and restored lymphocyte, monocyte, and white blood cell numbers, which were depleted in sepsis. Additionally, DSP_SK1260 enhanced function of the liver and kidney, as demonstrated by decreased serum ALT and creatinine levels, and improved liver histopathology. Importantly, therapeutic DSP_SK1260 treatment significantly prolonged survival in mice with polymicrobial sepsis induced by CLP, with a 72% increase over the control group. These findings highlight the therapeutic efficacy of DSP_SK1260 in both septic shock and polymicrobial sepsis models. DSP_SK1260 exhibited potent anti-inflammatory effects, preserved organ function, and improved survival rates. The results suggest that DSP_SK1260 holds promise as a potential treatment for sepsis, offering new avenues for targeted intervention in this life-threatening condition.
- 12 August 2026
- Published by Springer Nature in Research Square
Open AccessTherapeutic Efficacy of DSP_SK1260, an Immunomodulatory Peptide, in Experimental Models of Sepsis
Sepsis remains a significant healthcare challenge with limited effective treatments. In the present study, we investigated the therapeutic potential of DSP_SK1260, a novel compound with anti-inflammatory properties, in two sepsis models: E. coli BL21-induced septic shock and Caecal ligation and puncture (CLP) induced polymicrobial sepsis. In septic shock model, DSP_SK1260 administration before infection reduced proinflammatory cytokines, prevented disseminated intravascular coagulation (DIC), and improved survival rates in mice. Furthermore, when DSP_SK1260 was administered after sepsis induction, it effectively reduced TNF-α levels, improved coagulation parameters, and increased fibrinogen, platelet, and white blood cell counts. Therapeutic DSP_SK1260 treatment also enhanced survival in septic mice. In polymicrobial sepsis model induced by CLP, DSP_SK1260 treatment reduced TNF-α levels and restored lymphocyte, monocyte, and white blood cell numbers, which were depleted in sepsis. Additionally, DSP_SK1260 enhanced function of the liver and kidney, as demonstrated by decreased serum ALT and creatinine levels, and improved liver histopathology. Importantly, therapeutic DSP_SK1260 treatment significantly prolonged survival in mice with polymicrobial sepsis induced by CLP, with a 72% increase over the control group. These findings highlight the therapeutic efficacy of DSP_SK1260 in both septic shock and polymicrobial sepsis models. DSP_SK1260 exhibited potent anti-inflammatory effects, preserved organ function, and improved survival rates. The results suggest that DSP_SK1260 holds promise as a potential treatment for sepsis, offering new avenues for targeted intervention in this life-threatening condition.
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Synthesis and anticancer evaluation of novel quinazoline- piperazine linked 1,2,3-triazoles as potent Multi target anti-cancer agents
The development of multifunctional anticancer agents capable of simultaneously targeting multiple oncogenic pathways is an effective strategy to overcome tumor progression, metastasis, and therapeutic resistance. In the present study, a novel series of quinazoline–1,2,3-triazole–piperazine hybrids (8a–8p) was designed and synthesized based on the structural features of reference inhibitors erlotinib, lapatinib, phloretin, and AMD3100 for targeting EGFR, HER2, GLUT1, and CXCR4 pathways. Molecular docking studies revealed strong multi-target binding affinities, particularly for compounds 8j, 8k, 8i, and 8h. The synthesized derivatives exhibited potent concentration-dependent antiproliferative activity against H460 lung cancer, BT474 HER2-positive breast cancer, COS7 GLUT1-associated, and HCT116 colorectal cancer cell lines with low micromolar IC50 values. Compound 8j emerged as the most promising derivative, showing strong activity across all tested models. EGFR and HER2 kinase inhibition studies demonstrated potent inhibitory activity for compounds 8j, 8n, 8b, and 8i, while GLUT1 inhibition assays confirmed significant suppression of glucose uptake comparable to phloretin. Importantly, cytotoxicity studies in normal HBEC30KT and HEK293 cells revealed that compounds 8b and 8j exhibited comparatively low toxicity, indicating favorable therapeutic selectivity. Further mechanistic studies demonstrated that compounds 8b and 8j effectively inhibited cancer cell migration, suppressed anchorage-independent colony formation, induced apoptosis, and caused cell cycle arrest in multiple cancer cell lines. Overall, the present study identifies quinazoline–triazole–piperazine hybrids, particularly compound 8j, as promising multi-target anticancer candidates for further mechanistic and in vivo investigations.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSynthesis and anticancer evaluation of novel quinazoline- piperazine linked 1,2,3-triazoles as potent Multi target anti-cancer agents
The development of multifunctional anticancer agents capable of simultaneously targeting multiple oncogenic pathways is an effective strategy to overcome tumor progression, metastasis, and therapeutic resistance. In the present study, a novel series of quinazoline–1,2,3-triazole–piperazine hybrids (8a–8p) was designed and synthesized based on the structural features of reference inhibitors erlotinib, lapatinib, phloretin, and AMD3100 for targeting EGFR, HER2, GLUT1, and CXCR4 pathways. Molecular docking studies revealed strong multi-target binding affinities, particularly for compounds 8j, 8k, 8i, and 8h. The synthesized derivatives exhibited potent concentration-dependent antiproliferative activity against H460 lung cancer, BT474 HER2-positive breast cancer, COS7 GLUT1-associated, and HCT116 colorectal cancer cell lines with low micromolar IC50 values. Compound 8j emerged as the most promising derivative, showing strong activity across all tested models. EGFR and HER2 kinase inhibition studies demonstrated potent inhibitory activity for compounds 8j, 8n, 8b, and 8i, while GLUT1 inhibition assays confirmed significant suppression of glucose uptake comparable to phloretin. Importantly, cytotoxicity studies in normal HBEC30KT and HEK293 cells revealed that compounds 8b and 8j exhibited comparatively low toxicity, indicating favorable therapeutic selectivity. Further mechanistic studies demonstrated that compounds 8b and 8j effectively inhibited cancer cell migration, suppressed anchorage-independent colony formation, induced apoptosis, and caused cell cycle arrest in multiple cancer cell lines. Overall, the present study identifies quinazoline–triazole–piperazine hybrids, particularly compound 8j, as promising multi-target anticancer candidates for further mechanistic and in vivo investigations.
- Open Access
- 7 July 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14  (7) , e0004726
Multi-omics analysis of human patient samples identifies key immune factors in Leptospira infection
Leptospirosis is a globally neglected zoonotic disease caused by pathogenic Leptospira species and characterized by diverse clinical manifestations. However, the molecular immune responses occurring in circulating human immune cells during acute infection remain incompletely understood. Although several leptospiral virulence determinants have been investigated, a detailed characterization of host immune signaling during human infection is still limited. To characterize host molecular responses during acute leptospirosis, we performed integrated transcriptomic and proteomic profiling of peripheral blood mononuclear cells (PBMCs) from laboratory-confirmed leptospirosis patients and healthy controls. PBMCs were selected because they contain circulating immune cells involved in pathogen recognition and cytokine signaling, enabling focused analysis of host immune responses. Multi-omics network analysis was used to identify conserved immune pathways, and key host factors were further examined using ex vivo human whole-blood infection models and in vitro infection of human macrophages and monocytes. Transcriptomic profiling identified over 5,800 differentially expressed genes, predominantly upregulated, and associated with inflammatory signaling, including tumor necrosis factor signaling, interferon responses, and cytokine-mediated immune activation. Proteomic analyses detected 362 differentially expressed proteins in clinical PBMC samples and 818 differentially expressed proteins in the experimental infection model, with overlapping proteins defining a conserved host response. Comparative analysis identified 16 consistently upregulated host factors enriched in pathways related to neutrophil activation, hemostasis, and cytokine signaling. Quantitative RT-PCR confirmed increased expression of SERPINA1, BASP1, ORM1, NAMPT, and GCA, supporting their roles in inflammatory signaling and acute-phase immune responses. Together, these findings reveal conserved immune pathways activated during acute Leptospira infection and provide molecular insights into host-pathogen interactions in human leptospirosis. IMPORTANCE: Leptospirosis is a globally important zoonotic disease caused by bacteria of the genus Leptospira . It can lead to severe systemic complications such as kidney failure, lung injury, and multi-organ dysfunction in affected individuals. Accumulating evidence indicates that these severe clinical manifestations are closely associated with dysregulated host immune and inflammatory responses triggered during Leptospira infection. However, the molecular mechanisms underlying these immune responses, particularly the transcriptional and proteomic alterations occurring in human immune cells during infection, remain incompletely understood. In this study, we analyzed immune cells from patients with leptospirosis and identified key host molecules and immune pathways activated during infection. Experiments using human blood and immune cell models confirmed the involvement of several inflammatory host factors. These findings improve our understanding of how the human immune system responds to Leptospira infection and identify host-response molecules that may help guide future biomarker discovery and therapeutic strategies.
- 7 July 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14  (7) , e0004726
Open AccessMulti-omics analysis of human patient samples identifies key immune factors in Leptospira infection
Leptospirosis is a globally neglected zoonotic disease caused by pathogenic Leptospira species and characterized by diverse clinical manifestations. However, the molecular immune responses occurring in circulating human immune cells during acute infection remain incompletely understood. Although several leptospiral virulence determinants have been investigated, a detailed characterization of host immune signaling during human infection is still limited. To characterize host molecular responses during acute leptospirosis, we performed integrated transcriptomic and proteomic profiling of peripheral blood mononuclear cells (PBMCs) from laboratory-confirmed leptospirosis patients and healthy controls. PBMCs were selected because they contain circulating immune cells involved in pathogen recognition and cytokine signaling, enabling focused analysis of host immune responses. Multi-omics network analysis was used to identify conserved immune pathways, and key host factors were further examined using ex vivo human whole-blood infection models and in vitro infection of human macrophages and monocytes. Transcriptomic profiling identified over 5,800 differentially expressed genes, predominantly upregulated, and associated with inflammatory signaling, including tumor necrosis factor signaling, interferon responses, and cytokine-mediated immune activation. Proteomic analyses detected 362 differentially expressed proteins in clinical PBMC samples and 818 differentially expressed proteins in the experimental infection model, with overlapping proteins defining a conserved host response. Comparative analysis identified 16 consistently upregulated host factors enriched in pathways related to neutrophil activation, hemostasis, and cytokine signaling. Quantitative RT-PCR confirmed increased expression of SERPINA1, BASP1, ORM1, NAMPT, and GCA, supporting their roles in inflammatory signaling and acute-phase immune responses. Together, these findings reveal conserved immune pathways activated during acute Leptospira infection and provide molecular insights into host-pathogen interactions in human leptospirosis. IMPORTANCE: Leptospirosis is a globally important zoonotic disease caused by bacteria of the genus Leptospira . It can lead to severe systemic complications such as kidney failure, lung injury, and multi-organ dysfunction in affected individuals. Accumulating evidence indicates that these severe clinical manifestations are closely associated with dysregulated host immune and inflammatory responses triggered during Leptospira infection. However, the molecular mechanisms underlying these immune responses, particularly the transcriptional and proteomic alterations occurring in human immune cells during infection, remain incompletely understood. In this study, we analyzed immune cells from patients with leptospirosis and identified key host molecules and immune pathways activated during infection. Experiments using human blood and immune cell models confirmed the involvement of several inflammatory host factors. These findings improve our understanding of how the human immune system responds to Leptospira infection and identify host-response molecules that may help guide future biomarker discovery and therapeutic strategies.
- 16 April 2026
- Published by The ScienceIn Publishing in Chemical Biology Letters
- Vol. 13  (2) , 1766
Design, synthesis, molecular docking, and biological evaluation of Piperazine–Oxadiazole–Quinazoline hybrids as potential EGFR inhibitors for Lung cancer therapy
The development of novel epidermal growth factor receptor (EGFR) inhibitors with improved efficacy and selectivity remains a critical need in lung cancer therapy. In this study, a series of piperazine–oxadiazole–quinazoline hybrid compounds (7a–7p) was rationally designed, synthesized, and evaluated for their potential as EGFR-targeted anticancer agents. Molecular docking revealed strong binding affinities for all compounds to the EGFR tyrosine kinase domain, with binding energies ranging from –9.2 to –10.5 kcal/mol, indicating favourable interaction profiles within the active site. In vitro EGFR enzyme inhibition assays showed a broad spectrum of activity, with IC₅₀ values ranging from 0.4949 µM to 33.82 µM, confirming effective modulation of kinase activity. Cytotoxicity evaluation in normal HBEC30KT cells revealed significant variability across the series, with selected compounds showing high cell survival, indicating favourable safety profiles. Based on an integrated analysis of docking, enzymatic inhibition, and cytotoxicity, compounds 7b, 7k, and 7l were selected for further biological evaluation. These compounds demonstrated dose- and time-dependent inhibition of cell proliferation in A549 and H460 lung cancer cell lines, along with significant induction of apoptosis, as evidenced by increased apoptotic populations and accumulation of cells in the Sub-G1 phase. Additionally, the compounds effectively suppressed cell migration and reduced anchorage-independent growth, indicating inhibition of metastatic potential and tumorigenicity. Overall, the findings highlight the potential of these hybrid molecules as promising EGFR-targeted anticancer agents capable of modulating multiple hallmarks of cancer. Further studies focusing on mechanistic pathways and in vivo evaluation are warranted to advance their therapeutic development.
- 16 April 2026
- Published by The ScienceIn Publishing in Chemical Biology Letters
- Vol. 13  (2) , 1766
Design, synthesis, molecular docking, and biological evaluation of Piperazine–Oxadiazole–Quinazoline hybrids as potential EGFR inhibitors for Lung cancer therapy
The development of novel epidermal growth factor receptor (EGFR) inhibitors with improved efficacy and selectivity remains a critical need in lung cancer therapy. In this study, a series of piperazine–oxadiazole–quinazoline hybrid compounds (7a–7p) was rationally designed, synthesized, and evaluated for their potential as EGFR-targeted anticancer agents. Molecular docking revealed strong binding affinities for all compounds to the EGFR tyrosine kinase domain, with binding energies ranging from –9.2 to –10.5 kcal/mol, indicating favourable interaction profiles within the active site. In vitro EGFR enzyme inhibition assays showed a broad spectrum of activity, with IC₅₀ values ranging from 0.4949 µM to 33.82 µM, confirming effective modulation of kinase activity. Cytotoxicity evaluation in normal HBEC30KT cells revealed significant variability across the series, with selected compounds showing high cell survival, indicating favourable safety profiles. Based on an integrated analysis of docking, enzymatic inhibition, and cytotoxicity, compounds 7b, 7k, and 7l were selected for further biological evaluation. These compounds demonstrated dose- and time-dependent inhibition of cell proliferation in A549 and H460 lung cancer cell lines, along with significant induction of apoptosis, as evidenced by increased apoptotic populations and accumulation of cells in the Sub-G1 phase. Additionally, the compounds effectively suppressed cell migration and reduced anchorage-independent growth, indicating inhibition of metastatic potential and tumorigenicity. Overall, the findings highlight the potential of these hybrid molecules as promising EGFR-targeted anticancer agents capable of modulating multiple hallmarks of cancer. Further studies focusing on mechanistic pathways and in vivo evaluation are warranted to advance their therapeutic development.
- Open Access
- 13 March 2026
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 14, 1784084
Synthesis and antimicrobial activity of sulfonyl-imidazole linked fused isoxazolo[3,4-b][1,2,3]triazolo[4,5-d]pyridines:PEG-400 mediated one-pot reaction under ultrasonic irradiation
Introduction: The rapid emergence of methicillin-resistant and vancomycin-resistant Staphylococcus aureus (MRSA and VRSA) represents a major global health challenge, necessitating the development of new antibacterial scaffolds with improved efficacy and safety. Methods: In this study, a novel series of sulfonyl-imidazole-linked fused isoxazolo[3,4-b][1,2,3]triazolo[4,5-d]pyridine derivatives (6a–6o) was synthesized using a PEG-400-mediated, ultrasound-assisted one-pot Cu(I)-catalysed strategy under environmentally benign conditions. The synthesized compounds were evaluated for antibacterial activity against MSSA, MRSA, and VRSA strains, along with antibiofilm activity, hemolytic potential using mouse erythrocytes, and cytotoxicity in RAW 264.7, THP-1, and BoMac cells. Immunomodulatory effects were assessed through cytokine induction studies. Results: Several derivatives exhibited potent antibacterial activity, with compound 6k emerging as the most active candidate, displaying MIC values of 1.56–3.12 μg/mL and outperforming the reference drug dicloxacillin. Selected compounds also showed significant antibiofilm activity against resistant S. aureus strains. Hemolysis and cytotoxicity assays demonstrated minimal toxicity, indicating good biocompatibility. Immunomodulatory analysis revealed moderate cytokine induction, suggesting a controlled immune response. Discussion: Overall, compound 6k was identified as a promising lead with potent antibacterial, antibiofilm, and immunomodulatory properties, combined with a favourable safety profile, warranting further preclinical development against drug-resistant S. aureus infections.
- 13 March 2026
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 14, 1784084
Open AccessSynthesis and antimicrobial activity of sulfonyl-imidazole linked fused isoxazolo[3,4-b][1,2,3]triazolo[4,5-d]pyridines:PEG-400 mediated one-pot reaction under ultrasonic irradiation
Introduction: The rapid emergence of methicillin-resistant and vancomycin-resistant Staphylococcus aureus (MRSA and VRSA) represents a major global health challenge, necessitating the development of new antibacterial scaffolds with improved efficacy and safety. Methods: In this study, a novel series of sulfonyl-imidazole-linked fused isoxazolo[3,4-b][1,2,3]triazolo[4,5-d]pyridine derivatives (6a–6o) was synthesized using a PEG-400-mediated, ultrasound-assisted one-pot Cu(I)-catalysed strategy under environmentally benign conditions. The synthesized compounds were evaluated for antibacterial activity against MSSA, MRSA, and VRSA strains, along with antibiofilm activity, hemolytic potential using mouse erythrocytes, and cytotoxicity in RAW 264.7, THP-1, and BoMac cells. Immunomodulatory effects were assessed through cytokine induction studies. Results: Several derivatives exhibited potent antibacterial activity, with compound 6k emerging as the most active candidate, displaying MIC values of 1.56–3.12 μg/mL and outperforming the reference drug dicloxacillin. Selected compounds also showed significant antibiofilm activity against resistant S. aureus strains. Hemolysis and cytotoxicity assays demonstrated minimal toxicity, indicating good biocompatibility. Immunomodulatory analysis revealed moderate cytokine induction, suggesting a controlled immune response. Discussion: Overall, compound 6k was identified as a promising lead with potent antibacterial, antibiofilm, and immunomodulatory properties, combined with a favourable safety profile, warranting further preclinical development against drug-resistant S. aureus infections.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
Synthesis and biological evaluation of 1,2,3-triazolyl-sulfonyl-indole hybrids as potent antibacterial and immunomodulatory agents
The emergence of multidrug-resistant bacteria demands innovative antimicrobial agents with enhanced potency, broad-spectrum efficacy, improved safety, and reduced toxicity for effective infection control.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
Synthesis and biological evaluation of 1,2,3-triazolyl-sulfonyl-indole hybrids as potent antibacterial and immunomodulatory agents
The emergence of multidrug-resistant bacteria demands innovative antimicrobial agents with enhanced potency, broad-spectrum efficacy, improved safety, and reduced toxicity for effective infection control.
- Open Access
- 29 September 2025
- Published by Springer Nature in Communications Biology
- Vol. 8  (1) , 1-17
Adjuvant activity of a small molecule TLR4 agonist discovered via structure-based virtual screening
Monophosphoryl lipid A (MPLA), a TLR4 agonist, is a clinically approved vaccine adjuvant, but its complex structure and occasional toxicity limit broader use. Synthetic small-molecule TLR4 agonists offer advantages such as ease of synthesis, lower cost, and reduced toxicity. In this study, we conducted structure-based virtual screening of the ZINC database to identify novel TLR4-targeting small molecules across human, murine, and bovine species. Three lead compounds—NSF-418, NSF-501, and NSF-951—were selected based on favorable binding interactions and subjected to in vitro and in vivo evaluation. NSF-951 emerged as a potent TLR4 agonist, inducing strong proinflammatory cytokine responses (IL-6, TNF-α), upregulating CD80 and CD86 expression, and promoting macrophage maturation. Conversely, NSF-418 and NSF-501 acted as antagonists by suppressing MPLA-induced responses. In murine immunization studies, NSF-951, alone or with Alum (AF007), significantly enhanced OVA-specific antibody and T-cell responses without observable toxicity. These findings suggest that NSF-951 is a promising, cost-effective TLR4 agonist with strong immunostimulatory and adjuvant potential. Further studies are warranted to assess its performance with other antigens and adjuvant combinations, supporting its development as a next-generation adjuvant for veterinary and human vaccines.
- 29 September 2025
- Published by Springer Nature in Communications Biology
- Vol. 8  (1) , 1-17
Open AccessAdjuvant activity of a small molecule TLR4 agonist discovered via structure-based virtual screening
Monophosphoryl lipid A (MPLA), a TLR4 agonist, is a clinically approved vaccine adjuvant, but its complex structure and occasional toxicity limit broader use. Synthetic small-molecule TLR4 agonists offer advantages such as ease of synthesis, lower cost, and reduced toxicity. In this study, we conducted structure-based virtual screening of the ZINC database to identify novel TLR4-targeting small molecules across human, murine, and bovine species. Three lead compounds—NSF-418, NSF-501, and NSF-951—were selected based on favorable binding interactions and subjected to in vitro and in vivo evaluation. NSF-951 emerged as a potent TLR4 agonist, inducing strong proinflammatory cytokine responses (IL-6, TNF-α), upregulating CD80 and CD86 expression, and promoting macrophage maturation. Conversely, NSF-418 and NSF-501 acted as antagonists by suppressing MPLA-induced responses. In murine immunization studies, NSF-951, alone or with Alum (AF007), significantly enhanced OVA-specific antibody and T-cell responses without observable toxicity. These findings suggest that NSF-951 is a promising, cost-effective TLR4 agonist with strong immunostimulatory and adjuvant potential. Further studies are warranted to assess its performance with other antigens and adjuvant combinations, supporting its development as a next-generation adjuvant for veterinary and human vaccines.
- 18 July 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16  (9) , 4154-4169
New quinazoline-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of EGFR: synthesis, anti-breast cancer evaluation and in silico studies
Breast cancer is the most frequently diagnosed malignancy in women. Invasive breast cancer will be diagnosed in approximately one in every eight women during their lifetime. Quinazoline-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines were designed and synthesized using a pharmacophore hybridization technique that combined biologically active scaffolds. In vitro assays of the synthesized compounds' cancer activity against three breast cancer cell lines: MCF-7, MDA-MB-231, and MDA-MB-468, compounds 6i, 6k, and 6l exhibited significant activity. Compounds 6j and 6m exhibited equivalent efficacy relative to the standard drug against the MDA-MB-231 cell line, but compound 6i showed significant activity against the MDA-MB-468 cell line. Moreover, compound 6i (IC50 = 0.37 ± 0.03 μM) demonstrated superior efficacy compared to the standard erlotinib (IC50 = 0.42 ± 0.01 μM) in vitro, based on EGFR inhibitory assays and compound 6k (IC50 = 0.51 ± 0.04 μM) showed good EGFR inhibitory activity. To validate the activity data and the drug-likeness of the compounds, six potent compounds were subjected to in silico molecular docking investigations using the Discovery Studio 2021 methodology.
- 18 July 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16  (9) , 4154-4169
New quinazoline-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of EGFR: synthesis, anti-breast cancer evaluation and in silico studies
Breast cancer is the most frequently diagnosed malignancy in women. Invasive breast cancer will be diagnosed in approximately one in every eight women during their lifetime. Quinazoline-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines were designed and synthesized using a pharmacophore hybridization technique that combined biologically active scaffolds. In vitro assays of the synthesized compounds' cancer activity against three breast cancer cell lines: MCF-7, MDA-MB-231, and MDA-MB-468, compounds 6i, 6k, and 6l exhibited significant activity. Compounds 6j and 6m exhibited equivalent efficacy relative to the standard drug against the MDA-MB-231 cell line, but compound 6i showed significant activity against the MDA-MB-468 cell line. Moreover, compound 6i (IC50 = 0.37 ± 0.03 μM) demonstrated superior efficacy compared to the standard erlotinib (IC50 = 0.42 ± 0.01 μM) in vitro, based on EGFR inhibitory assays and compound 6k (IC50 = 0.51 ± 0.04 μM) showed good EGFR inhibitory activity. To validate the activity data and the drug-likeness of the compounds, six potent compounds were subjected to in silico molecular docking investigations using the Discovery Studio 2021 methodology.
- Open Access
Leptospira Lipid A Is a Potent Adjuvant That Induces Sterilizing Immunity against Leptospirosis
Leptospirosis is a globally significant zoonotic disease. The current inactivated vaccine offers protection against specific serovars but does not provide complete immunity. Various surface antigens, such as Leptospira immunoglobulin-like proteins (LigA and LigB), have been identified as potential subunit vaccine candidates. However, these antigens require potent adjuvants for effectiveness. Bacterial lipopolysaccharides (LPSs), including lipid A, are a well-known immunostimulant, and clinical adjuvants often contain monophosphoryl lipid A (MPLA). Being less endotoxic, we investigated the adjuvant properties of lipid A isolated from L. interrogans serovar Pomona (PLA) in activating innate immunity and enhancing antigen-specific adaptive immune responses. PLA activated macrophages to a similar degree as MPLA, albeit at a higher dose, suggesting that it is less potent in stimulation than MPLA. Mice immunized with a variable portion of LigA (LAV) combined with alum and PLA (LAV-alum-PLA) exhibited significantly higher levels of LAV-specific humoral and cellular immune responses compared to alum alone but similar to those induced by alum-MPLA. The adjuvant activity of PLA resembles that of MPLA and is primarily achieved through the increased recruitment, activation, and uptake of antigens by innate immune cells. Furthermore, like MPLA, PLA formulation establishes a long-lasting memory response. Notably, PLA demonstrated superior potency than MPLA formulation and provided sterilizing immunity against the leptospirosis in a hamster model. Overall, our study sheds light on the adjuvant properties of Leptospira lipid A and offers promising avenues for developing LPS-based vaccines against this devastating zoonotic disease.
Open AccessLeptospira Lipid A Is a Potent Adjuvant That Induces Sterilizing Immunity against Leptospirosis
Leptospirosis is a globally significant zoonotic disease. The current inactivated vaccine offers protection against specific serovars but does not provide complete immunity. Various surface antigens, such as Leptospira immunoglobulin-like proteins (LigA and LigB), have been identified as potential subunit vaccine candidates. However, these antigens require potent adjuvants for effectiveness. Bacterial lipopolysaccharides (LPSs), including lipid A, are a well-known immunostimulant, and clinical adjuvants often contain monophosphoryl lipid A (MPLA). Being less endotoxic, we investigated the adjuvant properties of lipid A isolated from L. interrogans serovar Pomona (PLA) in activating innate immunity and enhancing antigen-specific adaptive immune responses. PLA activated macrophages to a similar degree as MPLA, albeit at a higher dose, suggesting that it is less potent in stimulation than MPLA. Mice immunized with a variable portion of LigA (LAV) combined with alum and PLA (LAV-alum-PLA) exhibited significantly higher levels of LAV-specific humoral and cellular immune responses compared to alum alone but similar to those induced by alum-MPLA. The adjuvant activity of PLA resembles that of MPLA and is primarily achieved through the increased recruitment, activation, and uptake of antigens by innate immune cells. Furthermore, like MPLA, PLA formulation establishes a long-lasting memory response. Notably, PLA demonstrated superior potency than MPLA formulation and provided sterilizing immunity against the leptospirosis in a hamster model. Overall, our study sheds light on the adjuvant properties of Leptospira lipid A and offers promising avenues for developing LPS-based vaccines against this devastating zoonotic disease.